|
HN2005000795A
(es)
*
|
2004-10-15 |
2010-08-19 |
Aventis Pharma Inc |
Pirimidinas como antagonistas del receptor de prostaglandina d2
|
|
WO2006127587A1
(en)
*
|
2005-05-20 |
2006-11-30 |
Vertex Pharmaceuticals Incorporated |
Pyrrolopyridines useful as inhibitors of protein kinase
|
|
US8211919B2
(en)
|
2005-09-02 |
2012-07-03 |
Astellas Pharma Inc. |
Amide derivatives as rock inhibitors
|
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
WO2007076423A2
(en)
*
|
2005-12-22 |
2007-07-05 |
Smithkline Beecham Corporation |
INHIBITORS OF Akt ACTIVITY
|
|
CN102532133A
(zh)
|
2006-01-17 |
2012-07-04 |
沃泰克斯药物股份有限公司 |
适用作詹纳斯激酶抑制剂的吖吲哚类
|
|
EP2044061A2
(en)
*
|
2006-07-20 |
2009-04-08 |
Mehmet Kahraman |
Benzothiophene inhibitors of rho kinase
|
|
CL2007002617A1
(es)
*
|
2006-09-11 |
2008-05-16 |
Sanofi Aventis |
Compuestos derivados de pirrolo[2,3-b]pirazin-6-ilo; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar inflamacion de las articulaciones, artritis reumatoide, tumores, linfoma de las celulas del manto.
|
|
SG158147A1
(en)
|
2006-10-09 |
2010-01-29 |
Takeda Pharmaceutical |
Kinase inhibitors
|
|
AU2007338754A1
(en)
|
2006-12-21 |
2008-07-03 |
Vertex Pharmaceuticals Incorporated |
5-cyan0-4- (pyrrolo [2, 3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
|
|
DK2124944T3
(da)
|
2007-03-14 |
2012-04-23 |
Ranbaxy Lab Ltd |
Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer
|
|
CN101778825A
(zh)
*
|
2007-03-22 |
2010-07-14 |
沃泰克斯药物股份有限公司 |
适用作詹纳斯激酶抑制剂的n-杂环类化合物
|
|
JP5368485B2
(ja)
*
|
2008-02-25 |
2013-12-18 |
エフ.ホフマン−ラ ロシュ アーゲー |
ピロロピラジンキナーゼインヒビター
|
|
CA2716223A1
(en)
*
|
2008-02-25 |
2009-09-03 |
F. Hoffmann-La Roche Ag |
Pyrrolopyrazine kinase inhibitors
|
|
AU2009218609A1
(en)
*
|
2008-02-25 |
2009-09-03 |
F. Hoffmann-La Roche Ag |
Pyrrolopyrazine kinase inhibitors
|
|
ATE522536T1
(de)
*
|
2008-02-25 |
2011-09-15 |
Hoffmann La Roche |
Pyrrolopyrazin-kinasehemmer
|
|
ATE522534T1
(de)
*
|
2008-02-25 |
2011-09-15 |
Hoffmann La Roche |
Pyrrolopyrazin-kinasehemmer
|
|
WO2009145814A2
(en)
*
|
2008-03-10 |
2009-12-03 |
Vertex Pharmaceuticals Incorporated |
Pyrimidines and pyridines useful as inhibitors of protein kinases
|
|
US8119637B2
(en)
|
2008-06-10 |
2012-02-21 |
Plexxikon Inc. |
Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor
|
|
AU2009274023A1
(en)
*
|
2008-07-23 |
2010-01-28 |
Vertex Pharmaceuticals Incorporated |
Tri-cyclic pyrazolopyridine kinase inhibitors
|
|
MX2011000834A
(es)
*
|
2008-07-23 |
2011-04-05 |
Vertex Pharma |
Inhibidores de pirazolopiridin cinasa.
|
|
ES2402087T3
(es)
*
|
2008-07-23 |
2013-04-26 |
Vertex Pharmaceuticals Incorporated |
Inhibidores de la pirazolopiridina quinasa
|
|
EP2323659A4
(en)
*
|
2008-08-05 |
2012-03-14 |
Abbott Lab |
COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES
|
|
KR20170015566A
(ko)
|
2008-11-10 |
2017-02-08 |
버텍스 파마슈티칼스 인코포레이티드 |
Atr 키나제의 억제제로서 유용한 화합물
|
|
KR101361858B1
(ko)
*
|
2008-12-05 |
2014-02-12 |
에프. 호프만-라 로슈 아게 |
피롤로피라지닐 우레아 키나아제 저해제
|
|
ES2663222T3
(es)
|
2008-12-19 |
2018-04-11 |
Vertex Pharmaceuticals Incorporated |
Derivados de pirazina útiles como inhibidores de la quinasa ATR
|
|
RS57869B1
(sr)
|
2009-06-17 |
2018-12-31 |
Vertex Pharma |
Inhibitori replikacije virusa gripa
|
|
CA2767089A1
(en)
|
2009-07-15 |
2011-01-20 |
Abbott Laboratories |
Pyrrolopyridine inhibitors of kinases
|
|
CA2767091A1
(en)
*
|
2009-07-15 |
2011-01-20 |
Abbott Laboratories |
Pyrrolopyrazine inhibitors of kinases
|
|
PE20121336A1
(es)
|
2009-12-01 |
2012-11-03 |
Abbvie Inc |
Nuevos compuestos triciclicos
|
|
DE102009060175A1
(de)
|
2009-12-23 |
2011-06-30 |
Merck Patent GmbH, 64293 |
Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen
|
|
EP2528917B1
(en)
*
|
2010-01-27 |
2016-10-19 |
Vertex Pharmaceuticals Incorporated |
Pyrazolopyridines useful for the treatment of autoimmune, inflammatory or (hyper)proliferative diseases
|
|
WO2011094288A1
(en)
*
|
2010-01-27 |
2011-08-04 |
Vertex Pharmaceuticals Incorporated |
Pyrazolopyrazine kinase inhibitors
|
|
JP2013518112A
(ja)
*
|
2010-01-27 |
2013-05-20 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
ピラゾロピリジンキナーゼ阻害剤
|
|
CN101817823B
(zh)
*
|
2010-03-31 |
2012-09-12 |
上海毕得医药科技有限公司 |
4,7-二氮杂吲哚及其5位取代物的制备方法
|
|
AR081626A1
(es)
|
2010-04-23 |
2012-10-10 |
Cytokinetics Inc |
Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
|
|
AR081331A1
(es)
|
2010-04-23 |
2012-08-08 |
Cytokinetics Inc |
Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
|
|
US9133123B2
(en)
|
2010-04-23 |
2015-09-15 |
Cytokinetics, Inc. |
Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
|
|
JP2013529200A
(ja)
|
2010-05-12 |
2013-07-18 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
|
US9630956B2
(en)
|
2010-05-12 |
2017-04-25 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
JP2013526539A
(ja)
|
2010-05-12 |
2013-06-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用なピラジン
|
|
JP5856151B2
(ja)
|
2010-05-12 |
2016-02-09 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Atrキナーゼ阻害剤として有用な2−アミノピリジン誘導体
|
|
US8969356B2
(en)
|
2010-05-12 |
2015-03-03 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
JP2013526540A
(ja)
|
2010-05-12 |
2013-06-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ阻害剤として有用な化合物
|
|
CA2803802A1
(en)
*
|
2010-06-23 |
2011-12-29 |
Vertex Pharmaceuticals Incorporated |
Pyrrolo- pyrazine derivatives useful as inhibitors of atr kinase
|
|
EP2601192B1
(en)
*
|
2010-08-04 |
2017-03-01 |
Takeda Pharmaceutical Company Limited |
Fused heterocyclic compounds
|
|
TW201302793A
(zh)
|
2010-09-03 |
2013-01-16 |
Glaxo Group Ltd |
新穎之抗原結合蛋白
|
|
DE102010049877A1
(de)
*
|
2010-11-01 |
2012-05-03 |
Merck Patent Gmbh |
7-((1,2,3)Triazol-4-yl)-pyrrolo(2,3) pyrazinderivate
|
|
AU2011343642A1
(en)
|
2010-12-16 |
2013-05-02 |
Vertex Pharmaceuticals Incorporated |
Inhibitors of influenza viruses replication
|
|
US8754114B2
(en)
|
2010-12-22 |
2014-06-17 |
Incyte Corporation |
Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
|
|
US11466017B2
(en)
|
2011-03-10 |
2022-10-11 |
Board Of Regents, The University Of Texas System |
Heterocyclic inhibitors of PTPN11
|
|
JP2014510151A
(ja)
|
2011-04-05 |
2014-04-24 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
Atrキナーゼ(trakinase)阻害剤として有用なアミノピラジン化合物
|
|
US8759380B2
(en)
|
2011-04-22 |
2014-06-24 |
Cytokinetics, Inc. |
Certain heterocycles, compositions thereof, and methods for their use
|
|
WO2012178124A1
(en)
|
2011-06-22 |
2012-12-27 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
EP2723745A1
(en)
|
2011-06-22 |
2014-04-30 |
Vertex Pharmaceuticals Inc. |
Compounds useful as inhibitors of atr kinase
|
|
WO2012178125A1
(en)
|
2011-06-22 |
2012-12-27 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
UA118010C2
(uk)
|
2011-08-01 |
2018-11-12 |
Вертекс Фармасьютікалз Інкорпорейтед |
Інгібітори реплікації вірусів грипу
|
|
WO2013049719A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2013049859A1
(en)
|
2011-09-30 |
2013-04-04 |
Vertex Pharmaceuticals Incorporated |
Treating pancreatic cancer and non-small cell lung cancer with atr inhibitors
|
|
SG10201606774UA
(en)
|
2011-09-30 |
2016-10-28 |
Vertex Pharma |
Processes for making compounds useful as inhibitors of atr kinase
|
|
KR20140084112A
(ko)
|
2011-09-30 |
2014-07-04 |
버텍스 파마슈티칼스 인코포레이티드 |
Atr 키나제의 억제제로서 유용한 화합물
|
|
US8853217B2
(en)
|
2011-09-30 |
2014-10-07 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
US8841450B2
(en)
|
2011-11-09 |
2014-09-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
US8841337B2
(en)
|
2011-11-09 |
2014-09-23 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
WO2013071094A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2013071088A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase
|
|
WO2013071085A1
(en)
|
2011-11-09 |
2013-05-16 |
Vertex Pharmaceuticals Incorporated |
Pyrazine compounds useful as inhibitors of atr kinase
|
|
CA2869309C
(en)
|
2012-04-05 |
2021-02-09 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of atr kinase and combination therapies thereof
|
|
EP2858984A1
(en)
*
|
2012-06-08 |
2015-04-15 |
Vertex Pharmaceuticals Inc. |
Inhibitors of influenza viruses replication
|
|
ES2704744T3
(es)
|
2012-06-13 |
2019-03-19 |
Incyte Holdings Corp |
Compuestos tricíclicos sustituidos como inhibidores de FGFR
|
|
WO2014004863A2
(en)
*
|
2012-06-27 |
2014-01-03 |
Alzheimer's Institute Of America, Inc. |
Compounds, compositions, and therapeutic uses thereof
|
|
US9388185B2
(en)
|
2012-08-10 |
2016-07-12 |
Incyte Holdings Corporation |
Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
|
|
US8999632B2
(en)
|
2012-10-04 |
2015-04-07 |
Vertex Pharmaceuticals Incorporated |
Method for measuring ATR inhibition mediated increases in DNA damage
|
|
JP2015533151A
(ja)
*
|
2012-10-16 |
2015-11-19 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
セリン/スレオニンキナーゼ阻害剤
|
|
US8912198B2
(en)
|
2012-10-16 |
2014-12-16 |
Vertex Pharmaceuticals Incorporated |
Compounds useful as inhibitors of ATR kinase
|
|
SI2941432T1
(en)
|
2012-12-07 |
2018-07-31 |
Vertex Pharmaceuticals Incorporated |
2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
|
|
JP2016501251A
(ja)
*
|
2012-12-10 |
2016-01-18 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療のための新規二環フェニル−ピリジン/ピラジン
|
|
US9266892B2
(en)
|
2012-12-19 |
2016-02-23 |
Incyte Holdings Corporation |
Fused pyrazoles as FGFR inhibitors
|
|
JP2016512815A
(ja)
|
2013-03-15 |
2016-05-09 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
Atrキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体
|
|
EA035095B1
(ru)
|
2013-04-19 |
2020-04-27 |
Инсайт Холдингс Корпорейшн |
Бициклические гетероциклы в качестве ингибиторов fgfr
|
|
GB2515785A
(en)
*
|
2013-07-03 |
2015-01-07 |
Redx Pharma Ltd |
Compounds
|
|
WO2015026683A1
(en)
|
2013-08-22 |
2015-02-26 |
Merck Sharp & Dohme Corp. |
Compounds inhibiting leucine-rich repeat kinase enzyme activity
|
|
HRP20181272T1
(hr)
|
2013-11-13 |
2018-10-05 |
Vertex Pharmaceuticals Incorporated |
Postupci priprave inhibitora replikacije virusa influence
|
|
RS59144B1
(sr)
|
2013-11-13 |
2019-09-30 |
Vertex Pharma |
Inhibitori replikacije virusa influence
|
|
DK3077397T3
(da)
|
2013-12-06 |
2019-12-16 |
Vertex Pharma |
2-amino-6-fluor-n-[5-fluor-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamidforbindelse anvendelig som atr-kinase-inhibitor, dens fremstilling, forskellige faste former og radiomarkerede derivater deraf
|
|
PL3152212T3
(pl)
|
2014-06-05 |
2020-06-15 |
Vertex Pharmaceuticals Inc. |
Radioznakowane pochodne związku 2-amino-6-fluoro-n-[5-fluoro-piridyn-3-ylo]-pirazolo[1,5-a]pirymidino-3-karboksamidu przydatne jako inhibitor kinazy atr, wytwarzanie tego związku i jego różnych postaci stałych
|
|
LT3157566T
(lt)
|
2014-06-17 |
2019-08-12 |
Vertex Pharmaceuticals Incorporated |
Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
|
|
WO2016026078A1
(en)
*
|
2014-08-19 |
2016-02-25 |
Changzhou Jiekai Pharmatech Co., Ltd. |
Heterocyclic compounds as erk inhibitors
|
|
US10851105B2
(en)
|
2014-10-22 |
2020-12-01 |
Incyte Corporation |
Bicyclic heterocycles as FGFR4 inhibitors
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
MX373169B
(es)
|
2015-02-20 |
2020-04-24 |
Incyte Holdings Corp |
Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
|
|
WO2016134294A1
(en)
|
2015-02-20 |
2016-08-25 |
Incyte Corporation |
Bicyclic heterocycles as fgfr4 inhibitors
|
|
JP6857617B2
(ja)
|
2015-05-13 |
2021-04-14 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
インフルエンザウイルスの複製の阻害剤
|
|
JP6704416B2
(ja)
|
2015-05-13 |
2020-06-03 |
バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated |
インフルエンザウイルスの複製の阻害剤を調製する方法
|
|
CN107849046B
(zh)
*
|
2015-06-03 |
2020-06-12 |
常州捷凯医药科技有限公司 |
作为erk抑制剂的杂环化合物
|
|
CN106336413B
(zh)
*
|
2015-07-09 |
2021-04-20 |
广东东阳光药业有限公司 |
作为jak抑制剂的化合物及其用途
|
|
HK1258570A1
(zh)
|
2015-09-30 |
2019-11-15 |
Vertex Pharmaceuticals Inc. |
使用dna损伤剂及atr抑制剂的组合治疗癌症的方法
|
|
EP4088719A1
(en)
|
2015-10-13 |
2022-11-16 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
|
|
WO2017064119A1
(en)
|
2015-10-13 |
2017-04-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
|
|
US12365689B2
(en)
|
2015-10-16 |
2025-07-22 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11524964B2
(en)
|
2015-10-16 |
2022-12-13 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US10550126B2
(en)
|
2015-10-16 |
2020-02-04 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
EP3362455A1
(en)
|
2015-10-16 |
2018-08-22 |
AbbVie Inc. |
PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
|
|
US11365198B2
(en)
|
2015-10-16 |
2022-06-21 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11780848B2
(en)
|
2015-10-16 |
2023-10-10 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
|
|
US11512092B2
(en)
|
2015-10-16 |
2022-11-29 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
AU2017274199B2
(en)
|
2016-05-31 |
2021-09-23 |
Board Of Regents, The University Of Texas System |
Heterocyclic inhibitors of PTPN11
|
|
WO2018039539A1
(en)
|
2016-08-26 |
2018-03-01 |
Lycera Corporation |
Indazolyl-l,2,4-thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease
|
|
US10987354B2
(en)
*
|
2016-12-15 |
2021-04-27 |
Sunshine Lake Pharma Co., Ltd. |
Inhibitors of influenza virus replication and uses thereof
|
|
WO2018151830A1
(en)
*
|
2017-02-17 |
2018-08-23 |
Fronthera U.S. Pharmaceuticals Llc |
Pyridinyl based apoptosis signal-regulation kinase inhibitors
|
|
CN108948002A
(zh)
|
2017-05-19 |
2018-12-07 |
厦门大学 |
五元并六元氮杂芳环类化合物、其制备方法、药用组合物及其应用
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
EP3752161A4
(en)
*
|
2018-02-15 |
2021-12-22 |
Children's Hospital Medical Center |
METHOD OF TREATMENT OF FIBROSE
|
|
NZ766835A
(en)
|
2018-03-02 |
2023-09-29 |
Otsuka Pharma Co Ltd |
Pharmaceutical compounds
|
|
AU2019234574A1
(en)
|
2018-03-12 |
2020-09-03 |
Abbvie Inc. |
Inhibitors of tyrosine kinase 2 mediated signaling
|
|
KR102611661B1
(ko)
|
2018-05-02 |
2023-12-08 |
나비레 파르마, 인코퍼레이티드 |
Ptpn11의 치환된 헤테로사이클릭 억제제
|
|
MA52493A
(fr)
|
2018-05-04 |
2021-03-10 |
Incyte Corp |
Sels d'un inhibiteur de fgfr
|
|
CR20200590A
(es)
|
2018-05-04 |
2021-04-26 |
Incyte Corp |
Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
|
|
JP7174143B2
(ja)
|
2018-07-24 |
2022-11-17 |
大鵬薬品工業株式会社 |
Shp2活性を阻害するヘテロ二環性化合物
|
|
LT3833670T
(lt)
|
2018-08-10 |
2024-06-25 |
Navire Pharma, Inc. |
6-(4-amino-3-metil-2-oksa-8-azaspiro[4.5]dekan-8-il)-3-(2,3-dichlorfenil)-2-metilpirimidin-4(3h)-ono dariniai ir susiję junginiai kaip ptpn11 (shp2) inhibitoriai, skirti vėžiui gydyti
|
|
EP3845521B1
(en)
|
2018-08-31 |
2024-11-06 |
Suzhou Pengxu Pharmatech Co., Ltd. |
Synthesis methods for upadacitinib and intermediate thereof
|
|
EP3906026A4
(en)
|
2018-12-31 |
2022-10-19 |
Biomea Fusion, LLC |
IRREVERSIBLE INHIBITORS OF MENIN-MLL INTERACTION
|
|
WO2020185532A1
(en)
|
2019-03-08 |
2020-09-17 |
Incyte Corporation |
Methods of treating cancer with an fgfr inhibitor
|
|
JP7667097B2
(ja)
|
2019-06-14 |
2025-04-22 |
ヤンセン ファーマシューティカ エヌ.ベー. |
置換ピラゾロ-ピリジンアミド及びglun2b受容体調節因子としてのその使用
|
|
KR20220024403A
(ko)
|
2019-06-14 |
2022-03-03 |
얀센 파마슈티카 엔.브이. |
치환된 피라졸로-피라진 및 이들의 glun2b 수용체 조절제로서의 용도
|
|
TWI848141B
(zh)
*
|
2019-07-04 |
2024-07-11 |
英屬開曼群島商百濟神州有限公司 |
及其用途
|
|
WO2021007269A1
(en)
|
2019-07-09 |
2021-01-14 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
TW202116771A
(zh)
|
2019-07-17 |
2021-05-01 |
英屬開曼群島商百濟神州有限公司 |
作為hpk1抑制劑之三環化合物及其用途
|
|
GB201911928D0
(en)
|
2019-08-20 |
2019-10-02 |
Otsuka Pharma Co Ltd |
Pharmaceutical compounds
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
TWI891666B
(zh)
|
2019-10-14 |
2025-08-01 |
美商英塞特公司 |
作為fgfr抑制劑之雙環雜環
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
BR112022010664A2
(pt)
|
2019-12-04 |
2022-08-16 |
Incyte Corp |
Derivados de um inibidor de fgfr
|
|
EP4069696A1
(en)
|
2019-12-04 |
2022-10-12 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
WO2021146424A1
(en)
|
2020-01-15 |
2021-07-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
TW202304459A
(zh)
|
2021-04-12 |
2023-02-01 |
美商英塞特公司 |
包含fgfr抑制劑及nectin-4靶向劑之組合療法
|
|
WO2022261159A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
EP4352059A1
(en)
|
2021-06-09 |
2024-04-17 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
IL310717A
(en)
|
2021-08-20 |
2024-04-01 |
Biomea Fusion Inc |
Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
|
|
WO2024155710A1
(en)
|
2023-01-18 |
2024-07-25 |
Biomea Fusion, Inc. |
Crystalline forms of n-[4-[4-(4-morpholinyl)-7h-pyrrolo[2,3-d]pyrimidin-6- yl]phenyl]-4-[[3(r)-[(l-oxo-2-propen-l-yl)amino]-l-piperidinyl]methyl]-2-pyridinecarboxamide as a covalent inhibitor of menin-mll interaction
|
|
WO2025224050A1
(en)
|
2024-04-22 |
2025-10-30 |
Institut National de la Santé et de la Recherche Médicale |
Methods of treatment of patients suffering from hypomelanosis of ito
|